Residency · Residency · Otolaryngology
Cutaneous Malignancy of the Head and Neck
Overview
The head and neck region accounts for a disproportionately high percentage of cutaneous malignancies due to chronic sun exposure. Cutaneous squamous cell carcinoma (cSCC) and melanoma of the head and neck present unique surgical challenges given the cosmetic and functional importance of facial structures, complex lymphatic drainage, and proximity to critical nerves. The otolaryngologist plays a central role in managing advanced cutaneous malignancy, parotid metastases, and cervical nodal disease.
Cutaneous Squamous Cell Carcinoma (cSCC)
Epidemiology and Risk Factors
Second most common skin cancer; >1 million cases/year in the US. UV radiation is the primary risk factor. Immunosuppression (organ transplant recipients: 65-250x increased risk). Prior radiation therapy, chronic wounds, burn scars, Fair skin, increasing age, male predominance.
High-Risk Features (NCCN Criteria)
Size >2 cm, Depth >6 mm or invasion beyond subcutaneous fat, Poorly differentiated histology, Perineural invasion (named nerve involvement), Lymphovascular invasion, Recurrent tumor, Immunosuppressed patient. Location: ear, lip, temple, scalp. Desmoplastic or basosquamous subtypes.
Staging (AJCC 8th Edition)
T1: <= 2 cm. T2: >2-4 cm. T3: >4 cm or minor bone erosion, perineural invasion of named nerves, deep invasion (>6 mm). T4a: gross cortical bone or marrow invasion. T4b: skull base or axial skeleton invasion. Nodal staging mirrors mucosal head and neck SCC.
Management
Low-risk cSCC: excision with 4-6 mm margins; Mohs micrographic surgery for cosmetically sensitive areas. High-risk cSCC: wide excision (>6 mm margins) or Mohs surgery; consider adjuvant radiation for perineural invasion, positive margins, or multiple high-risk features. Nodal disease: neck dissection + adjuvant radiation +/- chemotherapy. Parotid metastasis: parotidectomy (superficial or total) + neck dissection + adjuvant RT. Unresectable/metastatic: immunotherapy (cemiplimab -- PD-1 inhibitor; FDA-approved for advanced cSCC).
Perineural Invasion
Named nerve involvement (facial, trigeminal branches) is a high-risk feature. Clinical PNI: numbness, pain, facial weakness, formication. Incidental PNI on pathology: adjuvant radiation recommended. MRI best imaging modality: nerve enhancement, enlargement, loss of fat planes. May track to skull base; extent of disease determines surgical vs. radiation approach.
Melanoma of the Head and Neck
Epidemiology
Head and neck melanoma accounts for 20-30% of all cutaneous melanomas. Worse prognosis than truncal or extremity melanoma (thicker tumors, more complex lymphatic drainage). Risk factors: UV exposure (intermittent intense > chronic), fair skin, dysplastic nevi, family history, CDKN2A mutations.
Subtypes
Superficial spreading: most common overall. Lentigo maligna: most common on the head and neck; arises in chronically sun-damaged skin of elderly patients; in situ precursor (lentigo maligna) may progress to lentigo maligna melanoma. Nodular: aggressive, vertical growth phase predominant. Desmoplastic/neurotropic: propensity for perineural invasion; high local recurrence; lower nodal metastasis rate.
Breslow Depth and Staging
Breslow thickness is the single most important prognostic factor. T1: <= 1.0 mm (a: <0.8 mm without ulceration; b: 0.8-1.0 mm or <0.8 mm with ulceration). T2: >1.0-2.0 mm. T3: >2.0-4.0 mm. T4: >4.0 mm. Ulceration upstages within each T category.
Surgical Margins
| Breslow Depth | Recommended Margin |
|---|---|
| In situ (lentigo maligna) | 5-10 mm (staged excision often needed) |
| ≤1.0 mm | 1 cm |
| 1.01-2.0 mm | 1-2 cm |
| >2.0 mm | 2 cm |
In situ (lentigo maligna): 5-10 mm margins; staged excision with margin control (modified Mohs) often needed due to subclinical extension. <= 1.0 mm depth: 1 cm margins. 1.01-2.0 mm: 1-2 cm margins. >2.0 mm: 2 cm margins. Head and neck anatomy often limits achieving ideal margins; modified margins with close follow-up may be necessary.
Sentinel Lymph Node Biopsy (SLNB)
Indicated for melanoma >= 0.8 mm Breslow depth or with ulceration. Head and neck lymphatic drainage is complex and unpredictable. Preoperative lymphoscintigraphy essential; drainage may be to parotid, cervical, postauricular, or occipital basins. Intraparotid sentinel nodes require superficial parotidectomy with facial nerve dissection. SLN positivity rate: 5-20% depending on Breslow depth. SLN positivity is the strongest predictor of outcome; guides need for completion lymph node dissection and adjuvant therapy.
Completion Lymph Node Dissection (CLND)
Historically performed for positive SLNB. DeCOG-SLT and MSLT-II trials: CLND did not improve melanoma-specific survival. Current practice shifting toward observation with ultrasound surveillance for positive SLNB. CLND still considered for clinically apparent nodal disease.
Adjuvant and Systemic Therapy
Immunotherapy: nivolumab, pembrolizumab (anti-PD-1); ipilimumab (anti-CTLA-4). Targeted therapy: dabrafenib + trametinib for BRAF V600E/K mutant melanoma. Adjuvant therapy indicated for stage III (node-positive) and resected stage IV. Neoadjuvant immunotherapy: emerging paradigm with high pathologic complete response rates.
Parotid Metastasis from Cutaneous Malignancy
Pathophysiology
Periauricular, temporal, and forehead skin drains to intraparotid and periparotid lymph nodes. Cutaneous SCC and melanoma are the most common primaries. Merkel cell carcinoma also has a high rate of parotid metastasis.
Management
Parotidectomy (superficial or total based on extent) with facial nerve preservation when possible. Concurrent ipsilateral neck dissection (levels I-V or selective II-IV). Adjuvant radiation therapy to the parotid bed and neck. Facial nerve sacrifice only if directly invaded by tumor; consider nerve grafting for reconstruction.
Merkel Cell Carcinoma
Rare, aggressive neuroendocrine skin cancer, Head and neck is the most common site, Associated with Merkel cell polyomavirus (MCPyV) in ~80%, Immunosuppression is a major risk factor, Wide excision (1-2 cm margins) + SLNB, High rate of nodal and distant metastasis, Adjuvant radiation to the primary site and regional nodes. Immunotherapy (avelumab, pembrolizumab) for metastatic disease.
<image>Diagram of head and neck cutaneous lymphatic drainage patterns. Illustration shows the face and scalp divided into drainage zones with arrows indicating lymphatic flow to first-echelon nodal basins. Anterior face and forehead drain to preauricular and intraparotid nodes. Temporal and periauricular skin drains to parotid and level II nodes. Posterior scalp drains to occipital and level V nodes. Central face drains to submandibular and submental nodes. Color-coded zones correspond to recommended neck dissection levels for each drainage pattern.</image>
<image>Clinical and histopathologic images of high-risk cutaneous SCC. Panel A: Clinical photograph of a large, ulcerated cSCC of the temple with satellite lesions. Panel B: Histopathology showing poorly differentiated SCC with perineural invasion around a named nerve branch (hematoxylin and eosin stain). Panel C: MRI showing enhancement and thickening of the infraorbital nerve (V2) indicating clinical perineural spread tracking toward the skull base. Panel D: Post-operative photograph after wide excision and local flap reconstruction.</image>
<image>Melanoma staging and management algorithm. Flowchart begins with biopsy-confirmed melanoma, branches by Breslow depth into margin recommendations and SLNB indications. For positive SLNB, pathway shows options for completion dissection versus observation with ultrasound surveillance. Adjuvant therapy decision nodes include BRAF mutation testing and selection between immunotherapy and targeted therapy. For advanced/metastatic disease, systemic therapy options are shown including combination immunotherapy and clinical trial enrollment.</image>
Clinical Pearls
Any cutaneous SCC with perineural invasion of a named nerve should prompt MRI of the nerve course to the skull base to evaluate for clinical perineural spread. Parotid metastasis from cutaneous malignancy requires parotidectomy with concurrent neck dissection and adjuvant radiation; outcomes are poor without multimodality treatment. Sentinel lymph node biopsy for head and neck melanoma requires preoperative lymphoscintigraphy because drainage patterns are highly variable and unpredictable. Desmoplastic melanoma has a high local recurrence rate but lower rate of nodal metastasis; wide margins and adjuvant radiation are more important than SLNB in some cases. Immunotherapy has transformed the management of advanced cutaneous SCC (cemiplimab) and melanoma (nivolumab/pembrolizumab), with durable responses in many patients. Lentigo maligna of the face often has extensive subclinical spread; staged excision with rush permanent sections or immunohistochemistry (MART-1/Melan-A) provides more accurate margin assessment than standard excision.
References
- NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 1.2024.
- NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2024.
- Faries MB, Thompson JF, Cochran AJ, et al. "Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma." N Engl J Med. 2017;376(23):2211-2222.
- Migden MR, Rischin D, Schmults CD, et al. "PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma." N Engl J Med. 2018;379(4):341-351.
- O'Brien CJ, McNeil EB, McMahon JD, et al. "Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland." Head Neck. 2002;24(5):417-422.
